TScan Therapeutics, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing TCR-engineered T cell therapies. Its 8-K filings furnish operating results, corporate presentations, and pipeline disclosures tied to TSC-101, the ALLOHA heme program, CD45-targeted candidates, solid-tumor research, and autoimmunity target discovery.
The company’s filings also cover governance and capital-structure matters, including officer role changes, compensation and retention arrangements, costs associated with portfolio prioritization, and proxy proposals for director elections, auditor ratification, and authorized common stock. The records identify TCRX voting common stock as listed on the Nasdaq Global Market.
TScan Therapeutics, Inc. reported a net loss of $28.7 million for the quarter ended March 31, 2026, compared with $34.1 million a year earlier, as research and development spending declined.
Collaboration and license revenue from its Amgen partnership was $982,000, down from $2.2 million, reflecting timing of research activities. Research and development expenses fell to $21.9 million from $29.8 million, mainly due to lower laboratory, facility and clinical costs after prioritizing its hematologic malignancy program.
The company ended the quarter with $128.1 million in cash and cash equivalents and total cash, cash equivalents and restricted cash of $133.1 million. Management believes this will fund its current operating plan into the second half of 2027 as it advances TCR-T cell therapy candidates, including lead program TSC-101 for acute myeloid leukemia and myelodysplastic syndrome.
TScan Therapeutics reported first quarter 2026 results and outlined upcoming clinical milestones. Revenue was $1.0 million for the quarter, down from $2.2 million a year earlier, mainly reflecting timing of work under its Amgen collaboration. Research and development expenses fell to $21.9 million from $29.8 million, and general and administrative expenses edged down to $8.2 million from $8.6 million, leading to a narrower net loss of $28.7 million versus $34.1 million in 2025. Cash and cash equivalents were $128.1 million as of March 31, 2026, and the company believes this will fund its operating plan into the second half of 2027. TScan plans to launch a Phase 3 study of TSC‑101 in AML and MDS in the second quarter of 2026, start a Phase 1 trial of CD45‑targeted candidates TSC‑102‑A01 and TSC‑102‑A03 in the second half of 2026, and share additional ALLOHA™ Phase 1 heme data during 2026.
TScan Therapeutics, Inc. is calling a virtual 2026 annual stockholder meeting on May 20, 2026, to vote on key governance and capital structure items. Stockholders of record as of April 15, 2026, may attend and vote online using a 16-digit control number.
The agenda includes electing two Class II directors, ratifying Deloitte & Touche LLP as auditor for 2026, and approving a charter amendment to double authorized voting common stock from 300,000,000 to 600,000,000 shares. A related proposal would allow adjourning the meeting to gather more proxies if support for the share increase is initially insufficient.
TScan Therapeutics is soliciting proxies for its virtual 2026 Annual Meeting on May 20, 2026 to elect two Class II directors, ratify Deloitte & Touche LLP as auditor, seek approval to increase authorized voting common stock from 300,000,000 to 600,000,000, and approve an adjournment option. The record date for voting is April 15, 2026. The board recommends a vote FOR all proposals; if Proposal 3 is not approved, Proposal 4 would permit adjournment to solicit additional proxies.
TScan Therapeutics, Inc. reported a leadership change in its finance organization. Leiden Dworak notified the company of his decision to resign as Vice President of Finance and principal accounting officer, effective April 10, 2026, and the company stated there were no disagreements regarding its operations, policies or practices.
The Board appointed Chief Financial Officer Jason A. Amello to also serve as principal accounting officer effective April 10, 2026. The company noted that Mr. Amello will not receive additional compensation for this added role and referenced its May 14, 2025 definitive proxy statement for information on his background, contracts and related party transactions.
TScan Therapeutics, Inc. presents an in-depth annual overview of its business and pipeline. The company focuses on T cell receptor-engineered T cell (TCR-T) therapies for hematologic cancers, solid tumors and autoimmune diseases, supported by an internal GMP manufacturing facility.
Lead candidate TSC-101 targets HA-2 in AML and MDS patients undergoing allogeneic transplantation. In the Phase 1 ALLOHA trial, relapse-free and overall survival trends favored TSC-101, with 3 of 3 patients two years post-transplant showing no evidence of disease versus 1 of 4 in the control arm, and no dose-limiting toxicities observed.
The FDA has agreed on a registrational path for TSC-101, and cleared INDs for follow-on heme candidates TSC-102-A01 and TSC-102-A03. The company has paused its solid tumor Phase 1 trial to prioritize its heme program and in vivo engineering for off-the-shelf multiplex TCR-T therapies.
TScan is also advancing an autoimmune discovery program and maintains a collaboration with Amgen in Crohn’s disease, under which it has received a $30.0 million upfront payment and is eligible for over $500 million in milestones plus tiered royalties.
TScan Therapeutics reported fourth-quarter and full-year 2025 results and outlined key clinical milestones. Revenue rose to $2.6M in Q4 2025 from $0.7M a year earlier, and to $10.3M for 2025 from $2.8M in 2024, mainly from its Amgen collaboration.
R&D expenses were $20.0M for Q4 and $114.2M for 2025, while G&A expenses were $6.4M for Q4 and $32.0M for 2025. Net loss narrowed to $23.0M in Q4 2025 from $35.8M in Q4 2024 and was $129.8M for 2025 versus $127.5M in 2024.
The company highlighted positive Phase 1 ALLOHA™ heme data, FDA clearance of INDs for CD45-targeting TSC-102-A01 and TSC-102-A03, completion of Cohort C enrollment, and plans to launch a pivotal trial for TSC-101 and start a Phase 1 study for TSC-102 candidates in 2026. Cash and cash equivalents were $152.4M as of December 31, 2025, which TScan believes will fund its operating plan into the second half of 2027.
TScan Therapeutics granted Chief Financial Officer Jason Amello a stock option for 350,000 shares of voting common stock on January 20, 2026. The option has an exercise price of $1.12 per share and was awarded at no cost to the executive. Following this grant, Amello beneficially owns options for 350,000 shares.
The award vests over time: 25% of the shares vest on the one-year anniversary of January 20, 2026, with the remaining 75% vesting in equal monthly installments over the next 36 months, conditioned on his continued service with the company.
TScan Therapeutics, Inc. granted stock options to its Chief Executive Officer and director, Gavin MacBeath. On January 20, 2026, he received a stock option to purchase 1,165,000 shares of voting common stock at an exercise price of $1.12 per share. The option was granted at no cost for the derivative itself.
According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on the one-year anniversary of January 20, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months. Vesting is conditioned on his continued service to the company on each vesting date. Following this grant, MacBeath beneficially owned 1,165,000 derivative securities directly.